RVTY

Business Context and Reporting Period

This Form 10-Q covers PerkinElmer, Inc. (note: the input metadata lists "REVVITY, INC." but the filing text identifies the registrant as PerkinElmer, Inc.) for the quarterly period ended October 4, 2009. The company operates in two primary segments: Human Health (diagnostics and research) and Environmental Health (environmental monitoring, safety, and laboratory services). The reporting period reflects a strategic realignment into these two segments effective at the start of fiscal year 2009.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased 9% ($41.7 million) in the quarter and 10% ($139.2 million) for the nine months compared to the prior year periods. This was driven by decreased demand in medical imaging, government stimulus-related order delays in the research market, and reduced spending by private testing labs and industrial customers.
• Profitability Pressure: Operating income from continuing operations fell 39% ($16.7 million) in the quarter and 26% ($31.1 million) for the nine months. Operating margins declined approximately 300 basis points in the quarter due to lower demand, restructuring charges, and increased pension expenses.
• Restructuring Charges: The company incurred $12.4 million in restructuring and lease charges for the quarter and $20.2 million for the nine months, primarily related to workforce reductions (337 employees total in Q1 and Q3 plans) and facility closures to align with growth strategies.
• Discontinued Operations: The company recorded a net loss of $1.6 million in the quarter and $3.6 million for the nine months related to the disposition of discontinued operations (including ViaCyte and Photonics businesses).

Guidance, Outlook, and Risks

• Outlook: Management anticipates continued pressure on lab budgets and credit availability but expects growth in the newborn screening business in the fourth quarter. The company believes its strategic focus on Human Health and Environmental Health positions it to weather the economic climate.
• Acquisitions: The company completed several acquisitions in the first nine months of 2009, including Sym-Bio LifeScience Co., Ltd. (China diagnostics), Analytica of Branford, Inc. (mass spectrometry), and Opto Technology Inc. (LED lighting), totaling approximately $122.7 million in cash used for acquisitions and investments.
• Liquidity: As of October 4, 2009, the company had $150.6 million in cash and $212.5 million available under its senior unsecured revolving credit facility. The company repurchased approximately 1.0 million shares of common stock for $14.2 million during the period.
• Risks: Key risks include the distressed global economy impacting end markets, credit availability constraints, foreign currency fluctuations (60% of business is outside the U.S.), and potential pension funding requirements (up to $18.0 million by end of fiscal 2010).
• Legal Contingencies: The company is involved in patent litigation with Enzo Biochem and PharmaStem Therapeutics. Management believes the resolution of these matters will not have a material adverse effect on financial statements.

Investor Verification Checklist

• Verify the sustainability of the 9% revenue decline and the specific impact of government stimulus delays on the research market.
• Confirm the timeline and total cost of the Q3 2009 and Q1 2009 restructuring plans, noting remaining liabilities of approximately $14.6 million.
• Assess the integration progress and revenue contribution of recent acquisitions (Sym-Bio, Analytica, Opto Technology).
• Monitor the status of the Enzo Biochem and PharmaStem patent litigation for potential future liabilities.
• Review the company's ability to meet pension funding obligations and the impact of rising pension costs on future operating margins.